Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.
about
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.Moonshot Objectives: Catalyze New Scientific Breakthroughs-Proteogenomics
P2860
Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.
@en
Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.
@nl
type
label
Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.
@en
Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.
@nl
prefLabel
Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.
@en
Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.
@nl
P2093
P2860
P1433
P1476
Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.
@en
P2093
Bradford R Hirsch
Geoffrey R Oxnard
Katharine H Wilcox
Lawrence H Schwartz
Mikhael Polotsky
Mithat Gonen
P2860
P304
P356
10.1001/JAMAONCOL.2015.6315
P577
2016-02-25T00:00:00Z